Abstract: Objective To compare the difference between SOX (oxaliplatin combined with sergio) and XELOX (oxaliplatin combined with capecitabine) in the incidence of adverse reactions after neoadjuvant chemotherapy for gastric cancer. Methods Changes in indicators and occurrence of adverse reactions after 3 cycles of SOX and XELOX neoadjuvant chemotherapy were recorded. Spss22.0 software was used to quantitatively and qualitatively compare the adverse reactions after neoadjuvant chemotherapy. Results A total of 97 patients with gastric cancer who met the criteria were included, including 68 cases in the SOX group and 29 cases in the XELOX group. In terms of bone marrow suppression after chemotherapy, erythrocytes decreased more significantly in the XELOX group than in the SOX group, and the difference was statistically significant (P =0.008). After chemotherapy, other indexes of the blood system decreased to a similar extent, and the difference was not statistically significant (P >0.05). After chemotherapy, the XELOX group was more vulnerable to leukopenia and neutropenia, and the difference was statistically significant (P<0.05).There was no statistically significant difference in the degree and incidence of liver and kidney function damage after chemotherapy (P>0.05). There was also no significant difference in the occurrence of gastrointestinal or other adverse reactions (mucositis, hand-foot syndrome, etc.) after chemotherapy between the two regimens (P>0.05).Conclusion XELOX neoadjuvant chemotherapy is more likely to induce bone marrow suppression after chemotherapy, and the decline in red blood cells after chemotherapy is more significant than in the SOX group. In terms of safety, SOX protocol is preferable as a neoadjuvant chemotherapy of gastric cancer in clinic.

Key words: gastric cancer, neoadjuvant chemotherapy, SOX, XELOX, .adverse reactions